Menicon Co., Ltd.

Melsplan, the industry's first flat-rate membership system introduced in 2001, reached 1.3 million members as of the end of March 2026, generating stable cash flow through fixed monthly fee income. Combined with initiatives to raise the proportion of members using 1-Day Disposable Contact Lenses, the company has also achieved a continuous increase in spending per customer.

The three sites—the General Research Institute, Techno Station, and Clinical Research Institute—work in organic coordination to handle everything in-house, from material development to safety evaluation and production technology development. R&D expenses for FY2026 (ending March 2026) totaled ¥5,561 million. The company continues to generate original products, including its in-house manufactured silicone hydrogel material product 1-Day Disposable Contact Lenses (1DAY Menicon Premio, etc.) and the world's first myopia progression control orthokeratology lens, Menicon Bloom Night, which obtained CE mark certification.

In addition to the Kakamigahara and Kasugai plants in Japan, the company operates production sites in Singapore, Malaysia (commercial production started February 2026), and China. Total capital expenditure for FY2026 (ending March 2026) was ¥15,171 million, and the Malaysia plant—the group's largest-footprint dedicated facility for 1-Day disposable lenses—began operations. Production output expanded 9.4% year on year to ¥24,951 million, strengthening the company's ability to respond to growing demand.

Domestically, the company is promoting an increase in the proportion of 1-Day disposable lens members within Melsplan. In Europe and North America, expansion of business with major mass retail chains continued, with European sales growing to ¥16,062 million in the current period (up from ¥14,442 million in the previous period). In China, groundwork is underway toward the launch of sales of silicone hydrogel material products.

In February 2026, Menicon Malaysia Sdn. Bhd. began commercial production, enhancing production capacity for 1-Day Disposable Contact Lenses. Expenditure for acquisition of property, plant and equipment in the current period continued at a large scale of ¥15,210 million. Cost reduction through mass production effects will be key to future profit margin improvement.

Demand is expanding in Japan and other Asian countries, with the company offering multiple lineups including Alpha Ortho K, Menicon Z Night, and Menicon Bloom Night (the industry's first CE-marked product for myopia progression control). In China, sales stagnated, declining by ¥350 million due to economic slowdown and intensifying competition; the company aims to turn this around through promotional support and academic information dissemination.

Under the slogan of the medium-term management plan "Vision2030," "A New 'Vision' for the World," the forecast for FY2027 (ending March 2027) is net sales of ¥133,000 million and operating profit of ¥11,000 million. Achieving the target requires an additional increase of over ¥7,000 million in net sales and a substantial improvement in operating margin from the current 8% range to 12% over the remaining two periods, and progress remains halfway toward the goal.